Traditional Chinese medicine composition for treating type 2 diabetes and application thereof

Abstract

The invention provides a traditional Chinese medicine composition for treating type 2 diabetes and application thereof, and belongs to the technical field of traditional Chinese medicine, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 6 g of chamomile, 6 g of corn stigma, 6 g of jerusalem artichoke, 6 g of inonotuso bliquus and 6 g of snow tea. The invention aims to provide a traditional Chinese medicine composition for treating type 2 diabetes and application thereof. The composition disclosed by the invention can be used for rapidly and effectively relieving type 2 diabetes symptoms such as polydipsia, polyphagia, diuresis and body emaciation of patients. The traditional Chinese medicine is prepared from roots, stems, leaves, flowers, fruits and seeds of pure natural plants, has no toxic or side effect, is mainly used for treating type 2 diabetes and has a remarkable clinical effect.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicine, and in particular to a traditional Chinese medicine composition for treating type 2 diabetes and application thereof. Background Art

[0002] Diabetes is an endocrine metabolic disease characterized by chronic hyperglycemia, which is caused by the combined effects of genetic and environmental factors, leading to defects in insulin secretion or (and) action. More than 90% of diabetic patients suffer from type 2 diabetes, and its rapid increase is related to changes in diet and physical activity related to rapid development and urbanization, and is gradually becoming younger. Type 2 diabetes is a multi-source disease with insulin resistance and relative lack of insulin secretion as the basic mechanism of pathogenesis. The body first develops a certain degree of insulin resistance, and the pancreatic β cells can no longer respond to the increasing demand for insulin, which leads to disorders in glucose and lipid metabolism and causes continuous increase in blood sugar. Clinically, it manifests as symptoms such as polydipsia, polyphagia, polyuria, and body weight loss. It has the characteristics of high incidence and long course of disease. In addition, continuous high blood sugar can induce acute complications such as diabetic ketoacidosis and hyperosmolar diabetic syndrome, as well as multiple chronic complications such as macrovascular disease, microvascular disease, neuropathy, and infection. To date, the treatment of type 2 diabetes is mainly based on controlling blood sugar, through oral administration of hypoglycemic drugs such as metformin, sulfonylureas or injection of insulin and its analogs to control blood sugar. However, small molecule chemical drugs have a single target, and although they can quickly exert a blood sugar-lowering effect, they cannot cure the disease. Long-term use can easily lead to risks of hypoglycemia, drug dependence, toxic and side effects, and there are limitations in clinical use. Therefore, it is urgent to explore ways to treat type 2 diabetes. Summary of the invention

[0003] In view of the problems existing in the prior art, the purpose of the present invention is a Chinese medicine composition for treating type 2 diabetes and its application. The composition of the present invention can effectively relieve the symptoms of type 2 diabetes, and can quickly and effectively relieve the symptoms of type 2 diabetes such as polydipsia, polyphagia, polyuria and body weight loss in patients. The drugs used are all medicinal and edible plants, without any toxic side effects, and are mainly used to treat type 2 diabetes with significant clinical effects.

[0004] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions.

[0005] The invention discloses a traditional Chinese medicine composition for treating type 2 diabetes, characterized in that the composition is composed of the following raw materials: chamomile, corn silk, Jerusalem artichoke, chaga and white snow tea.

[0006] Furthermore, the Chinese medicine composition is composed of the following raw materials by weight: 6g chamomile, 6g corn silk, 6g Jerusalem artichoke, 6g chaga, and 6g white snow tea.

[0007] The present invention also discloses a use of the Chinese medicine composition according to any one of the above items in preparing a medicine for treating type 2 diabetes.

[0008] The invention discloses a pharmaceutical composition, characterized in that the components include any one of the above-mentioned traditional Chinese medicine compositions and a pharmaceutically acceptable carrier.

[0009] Furthermore, the dosage form of the pharmaceutical composition is a pharmaceutically acceptable dosage form.

[0010] Furthermore, use of any of the above-mentioned pharmaceutical compositions in the preparation of drugs for treating type 2 diabetes.

[0011] The invention discloses a method for preparing the above-mentioned traditional Chinese medicine composition for treating type 2 diabetes, which is characterized by comprising the following steps: weighing chamomile, corn silk, Jerusalem artichoke, chaga and snow tea according to weight, adding water for decoction, and collecting the decoction.

[0012] Furthermore, the decoction with water is performed by using 8 times the amount of distilled water, soaking overnight, adding 8 times the amount of water for the first decoction and decocting for 2 hours, and adding 6 times the amount of water for the second decoction and decocting for 1.5 hours, and the medicinal liquids obtained by filtering the two decoctions are mixed to obtain the Chinese medicine composition.

[0013] Compared with the prior art, the beneficial effects of the present invention are as follows.

[0014] 1. Compared with the small molecule chemical drugs commonly used in clinical practice, the drug of the present invention has the remarkable effect of:

[0015] (1) The present invention addresses the root cause of the disease and, under the guidance of the TCM concept of organization and treatment based on syndrome differentiation, regulates the balance of yin and yang in the human body and can effectively treat type 2 diabetes.

[0016] (2) The pathogenesis of type 2 diabetes is complex. The present invention overcomes the difficulty of small molecule chemical drugs having a single target, making the scope of action more comprehensive and lasting, and can effectively improve the body's insulin resistance and promote insulin secretion.

[0017] (3) Compared with small molecule chemical drugs that inevitably produce adverse reactions and risks such as drug dependence after long-term use, the drugs of the present invention use roots, stems, leaves, flowers, fruits and seeds of pure natural plants, with fewer side effects, high ingredient safety and fewer adverse reactions.

[0018] 2. Compared with the existing Chinese medicine composition invention technology, the present invention has the remarkable effect of:

[0019] The prescription of the present invention has the effects of invigorating qi and nourishing yin, clearing heat and promoting body fluid. In the prescription, the small Jerusalem artichoke with cool nature, sweet and slightly bitter taste clears heat and detoxifies, invigorates qi and nourishes blood, nourishes yin and moistens dryness, removes fire and dryness, promotes body fluid and invigorates qi, and is the main medicine; the chamomile with slightly cold nature, sweet and slightly bitter taste clears heat and removes dampness and detoxifies, and the corn silk with sweet and flat nature and flavor clears blood heat, promotes urination, removes heat from the stool, and retains qi and yin, which are the ministerial medicines; white snow tea and chaga mushroom clear heat and promote body fluid, invigorate qi and nourish yin, purge heart fire, and nourish the yin water of the lungs and kidneys, which are the adjuvants. The whole prescription plays the role of invigorating qi and nourishing yin, clearing heat and promoting body fluid. Type 2 diabetes is a disease characterized by yin and body fluid deficiency as the main symptom and excessive dryness and heat as the target. These five medicines complement each other and play the effects of invigorating qi and nourishing yin, clearing heat and promoting body fluid, and effectively alleviate the symptoms of polydipsia, polyphagia, polyuria and body weight loss in patients with type 2 diabetes. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 The effect of Jiangtang prescription on the general morphology of rats with type 2 diabetes. A: body weight; B: food intake; C: water intake; D: urine output. Note: Compared with the normal group, #P<0.05, ##P<0.01; compared with the model group, *P<0.05, **P<0.01.

[0021] Figure 2 The effect of Jiangtang prescription on glucose metabolism in rats with type 2 diabetes. A: fasting blood glucose value; B: oral glucose tolerance; C: area under the blood glucose curve. Note: Compared with the normal group, #P<0.05, ##P<0.01; compared with the model group, *P<0.05, **P<0.01.

[0022] Figure 3 The effect of Jiangtang prescription on insulin resistance in rats with type 2 diabetes. A: Glycated serum protein content; B: Fasting insulin content; C: Insulin resistance index; D: Insulin secretion index. Note: Compared with the normal group, #P<0.05, ##P<0.01; compared with the model group, *P<0.05, **P<0.01.

[0023] Figure 4 The effect of Jiangtang prescription on organ indexes of rats with type 2 diabetes. A: pancreas index; B: liver index; C: kidney index. Note: Compared with the normal group, #P<0.05, ##P<0.01; compared with the model group, *P<0.05, **P<0.01.

[0024] Figure 5 The effect of Jiangtang prescription on the pathological morphology of pancreatic tissue in rats with type 2 diabetes. A: HE staining of rat pancreatic tissue (×50); B: HE staining of rat pancreatic tissue (×200); C: pathological score of rat pancreatic tissue. Note: Compared with the normal group, #P<0.05, ##P<0.01; compared with the model group, *P<0.05, **P<0.01. DETAILED DESCRIPTION

[0025] The present invention is further described in detail below with specific embodiments, but it should not be understood that the scope of the above subject matter of the present invention is limited to the following embodiments, and all technologies realized based on the content of the present invention belong to the scope of the present invention.

[0026] Unless otherwise specified, all reagents and materials used in the present invention are commercially available.

[0027] 1 Experimental materials.

[0028] 1.1 Experimental animals

[0029] Thirty-four 6-week-old clean grade (SPF) SD rats, male, weighing (200±10) g, were provided by Liaoning Changsheng Biotechnology Co., Ltd., with animal production license number SCXK(Liao)2020-0001 and animal quality certificate number No.210726231102036567. The animals were housed in the SPF Experimental Animal Center of Liaoning University of Traditional Chinese Medicine, with free access to food and water, temperature of 18-23°C, humidity of 35%-55%, 12h light-dark cycle, and adaptive feeding for 1 week. This experiment was reviewed and approved by the Ethics Committee of Liaoning University of Traditional Chinese Medicine, with approval number 21000042023135.

[0030] 1.2 Drugs and reagents.

[0031] The hypoglycemic prescription was provided by the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine. It consists of 5 herbs, including 6g of chamomile, 6g of corn silk, 6g of Jerusalem artichoke, 6g of chaga, and 6g of white snow tea. The above herbs were soaked overnight with 8 times the amount of distilled water. The first decoction was decocted with 8 times the amount of water for 2h, and the second decoction was decocted with 6 times the amount of water for 1.5h. The medicinal liquids obtained by filtering the two decoctions were mixed, heated and concentrated into a suspension with a concentration of 3.2g / mL, and refrigerated in a refrigerator at 4℃ and rewarmed before use. Dimethoate hydrochloride tablets were provided by Merck Pharmaceuticals Co., Ltd. with a specification of 0.5g / tablet, which was prepared and used immediately. Streptozotocin (STZ) was purchased from Yishen Biotechnology Co., Ltd.

[0032] 1.3 Instruments.

[0033] Yuyue blood glucose meter and supporting blood collection needles and test strips (Yuyue Kailite Biotechnology Co., Ltd.); MIKRO220 ultra-speed low-temperature centrifuge (Hettich, Germany); C×23 optical microscope (Olympus Biotechnology Co., Ltd.); embedding machine (Leica, Germany); HS-S7220-B electric paraffin slicer (Shenyang Hengsong Technology Co., Ltd.); microscope (Leica, Germany); BDF-86V158 low-temperature refrigerator (Boke Biotechnology Co., Ltd.); ELISA reader (Molecular Devices, USA).

[0034] 2 Experimental methods.

[0035] 2.1 Modeling and grouping.

[0036] Six of 34 6-week-old SPF SD rats were randomly selected as the normal control group (NC), and were given a normal diet and free drinking water; the remaining 28 SD rats were used as the model group, and were fed with a high-fat and high-sugar diet (10% lard, 8% egg yolk powder, 1.5% cholesterol, 20% sucrose, 0.1% sodium cholate and 60.4% conventional feed, purchased from Xiaoshu Youtai Biotechnology Co., Ltd.) for 6 weeks and had normal drinking water. On the first day of the 7th week, the rats in the model group were fasted for more than 12 hours, and the rats in the NC group were intraperitoneally injected with 30 mg / kg of STZ solution, and the rats in the NC group were intraperitoneally injected with an equal dose of 30 mg / kg of citric acid buffer, and were closely observed for 72 hours after injection. After 72 hours, the tail tip of the rats was disinfected with 75% alcohol and blood was collected. Blood glucose was measured using a Yuyue blood glucose meter and blood glucose test strips. When it was ≥16.7mmol / L, the model was successfully established. The model group rats with blood glucose <16.7mmol / L were injected with STZ solution 30mg / kg intraperitoneally again and closely observed for 72 hours after injection. After 72 hours, the tail tip of the rats was disinfected with 75% alcohol and blood glucose was collected. Blood glucose was measured using a Yuyue blood glucose meter and blood glucose test strips. When it was ≥16.7mmol / L, the model was successfully established. The rats with successful modeling were randomly divided into a model group (Model), a Jiangtang prescription treatment group (JTF), a Jiangtang prescription combined with metformin treatment group (JTF+MET), and a metformin treatment group (MET).

[0037] 2.2 Method of administration.

[0038] After successful modeling, drug intervention was started. Rats in the NC group and the Model group were gavaged with 2 mL of distilled water, the JTF group was gavaged with 16 g / kg, the JTF+MET group was gavaged with 16 g / kg of Jiangtang Fang combined with 0.15 g / kg of metformin hydrochloride, and the MET group was gavaged with 0.15 g / kg of metformin hydrochloride, once a day, for 4 consecutive weeks. During this period, rats in the NC group were fed with ordinary feed, and rats in the other groups were fed with high-fat and high-sugar feed and had normal drinking water.

[0039] 2.3 Material collection and processing.

[0040] After the last oral administration, the rats were fasted but not watered for more than 12 hours, and anesthetized with 8% sodium pentobarbital at 0.2 mL / 100 g intraperitoneally according to their body weight. Blood was collected from the abdominal aorta, and part of the blood was stored in an anticoagulant tube for standby use. Part of the blood was centrifuged for 15 minutes (speed 2500 r / min, 4°C), serum was separated, and the supernatant was taken and stored in a -80°C refrigerator. The rats were killed, and the pancreas, liver, and kidneys were removed by opening the abdomen on an ice pack, washed with saline, dried with filter paper, and weighed quickly for calculation of the rat organ index. After the pancreas was weighed, the following method was performed on the ice pack: the pancreas was divided into two, one half was fixed in 4% paraformaldehyde and made into paraffin sections for staining observation; the other half was stored in a -80°C low-temperature refrigerator for subsequent extraction and detection of related proteins.

[0041] 3. Detection indicators and methods.

[0042] 3.1 General morphological observation.

[0043] During the experiment, the weight changes of rats were monitored once a week; the food intake, water intake and urine output of rats should be recorded in metabolic cages on the first day of each week during the experiment.

[0044] 3.2 Blood glucose monitoring.

[0045] During the experiment, fasting blood glucose (FPG) was monitored before and after modeling and at each medication period (1 week / time), and an oral glucose tolerance test (OGTT) was performed. Rats were fasted but not watered for more than 12 hours, the tip of the rat tail was disinfected with an alcohol cotton pad, and the tip of the tail was punctured with a disposable blood collection needle to collect blood. The fasting blood glucose of the rat was tested and recorded with a blood glucose meter and blood glucose test strips; after the fasting blood glucose was tested (before intragastric administration, i.e., 0 min), 50% glucose injection was administered intragastrically at 2 g / kg, and the blood glucose values ​​were measured at 30 min, 60 min, 120 min, and 180 min after intragastric administration, and the area under the curve (AUC) was calculated.

[0046] AUC=[1 / 4 (0min) + 1 / 2 (30min) + 3 / 4 (60min) + (120min) + 1 / 2(180min)].

[0047] 3.3 Serum index detection.

[0048] The rat serum stored in -80℃ refrigerator was taken out and rewarmed at room temperature. The operation steps in the instructions of the glycosylated serum protein (GSP) and fasting insulin (FINS) kit were used to standardize the operation, add the sample carefully, compare the color with the microplate reader, and calculate the results according to the formula. According to the FBG and FINS levels, the homeostatic model assessment of insulin resistance index (HOMA-IR) and insulin secretion index (HOMA-β) were calculated.

[0049] The calculation formula is as follows: HOMA-IR=(FBG×FINS)÷22.5; HOMA-β=(20×FINS)÷(FBG−3.5).

[0050] 3.4 Organ index detection.

[0051] Weigh the wet weight of the rat liver, kidney and pancreas, and calculate the rat organ index according to the formula: Organ index = organ wet weight ÷ rat total weight × 100%.

[0052] 3.5 Pancreatic histopathological observation and scoring.

[0053] The pancreatic tissue fixed with 4% paraformaldehyde solution was dehydrated, waxed, embedded, sliced ​​and dried step by step, and stained with HE staining kit. After dehydration and sealing, the morphological structure of rat pancreatic tissue was examined under an optical microscope to judge whether there were any damage lesions. The pancreatic tissue damage was scored according to the severity and extent of pancreatic tissue interstitial edema, inflammatory cell infiltration, and acinar cell necrosis. The scoring criteria are shown in Table 1.

[0054] Table 1 Scoring criteria for pancreatic inflammation and injury .

[0055] Note: It is divided into interstitial edema (E), inflammatory cell infiltration (I) and apical cell necrosis (N), and each item is scored as 1, 2 and 3 points respectively according to the severity of the disease. The scoring formula for pancreatic inflammation activity is P+L+N.

[0056] 5Results.

[0057] 5.1 Effects of the Jiangtang recipe on the general morphology of type 2 diabetic rats.

[0058] During the period of 6-12 weeks of age, there was no statistically significant difference in body weight between rats fed a high-sugar and high-fat diet and rats fed a normal diet (P>0.05); at the 13th week of age, after intraperitoneal injection of STZ solution, the body weight of rats with successful modeling was significantly lower than that of rats in the NC group (P<0.01). This may be because STZ can selectively destroy the pancreatic β cells of rats, promote the development of DM in rats, and cause serious disorders in the glucose and lipid metabolism of rats, resulting in rapid weight loss. After 4 weeks of drug intervention, compared with the NC group, the body weight of rats in the Model group showed a significant downward trend (P<0.01); compared with the Model group, the body weight of rats in the JTF+MET group showed a gradual upward trend (P<0.05), indicating that the hypoglycemic prescription can improve the symptoms of weight loss in diabetes, see Figure 1After 4 weeks of drug intervention, compared with the NC group, the food intake, water intake and urine volume of the rats in the Model group increased significantly (P<0.01); compared with the Model group, the food intake, water intake and urine volume of the rats in the three treatment groups decreased significantly (P<0.01), and the decrease was more obvious in the JTF+MET group, indicating that the hypoglycemic prescription can effectively improve the symptoms of polydipsia, polyphagia and polyuria in type 2 diabetes. Figure 1 .

[0059] 5.2 Effect of the Jiangtang prescription on glucose metabolism in type 2 diabetic rats.

[0060] After 4 weeks of drug intervention, compared with the NC group, the FPG of the rats in the Model group was significantly increased (P<0.01); compared with the Model group, the FPG of the rats in the three treatment groups was significantly decreased (P<0.01), and the decrease was more obvious in the JTF+MET group, indicating that the Jiangtang prescription has a very obvious hypoglycemic effect. Figure 2 After 4 weeks of drug intervention, compared with the NC group, the blood glucose levels of the rats in the Model group were significantly increased at all time periods (P<0.01), and after 180 minutes, the blood glucose levels still did not return to the postprandial level, and the AUC increased significantly (P<0.01). Compared with the Model group, the blood glucose levels of the rats in the three treatment groups were reduced at all time periods (P<0.05), and the AUC decreased significantly (P<0.01), especially in the JTF+MET group, where the blood glucose levels at all time periods decreased significantly (P<0.01), indicating that the hypoglycemic prescription can improve the blood glucose regulation ability of rats with type 2 diabetes. Figure 2 .

[0061] 5.3 Effect of Jiangtang prescription on insulin resistance in rats with type 2 diabetes.

[0062] After 4 weeks of drug intervention, the GSP level of rats in the Model group was significantly increased compared with that in the NC group (P<0.01); compared with the NC group, the GSP levels of rats in the three treatment groups were significantly decreased, and the decrease in the JTF+MET group was more obvious, with statistically significant differences (P<0.01), indicating that the Jiangtang prescription can effectively reduce the blood glucose level of diabetic rats. Figure 3 After 4 weeks of drug intervention, compared with the NC group, the FINS level and HOMA-β of the rats in the Model group were significantly decreased (P<0.01), and the HOMA-IR was significantly increased (P<0.01); compared with the NC group, the FINS level and HOMA-β of the rats in the three treatment groups were significantly increased, and the HOMA-IR was significantly decreased, among which the change in the JTF+MET group was more obvious, and the difference was statistically significant (P<0.01), indicating that the hypoglycemic prescription can effectively improve the function of pancreatic islet cells, reduce the insulin resistance of rats with type 2 diabetes, and promote insulin secretion. Figure 3 .

[0063] 5.4 Effects of the hypoglycemic prescription on organ indexes of type 2 diabetic rats.

[0064] After 4 weeks of drug intervention, the pancreatic index of rats in the Model group was significantly increased compared with that in the NC group (P<0.01), indicating that the pancreas of diabetic model rats was inflammatory and edematous. Compared with the Model group, the pancreatic index of rats in the three treatment groups was significantly decreased (P<0.01), and the pancreatic index of the JTF+MET group decreased more significantly, indicating that the hypoglycemic prescription can improve the pancreatic cell necrosis and edema in diabetic rats. Figure 4 After 4 weeks of drug intervention, the liver index of rats in the Model group increased compared with that in the NC group (P<0.05). This may be because the long-term high-fat and high-sugar diet of rats led to fatty changes in the liver and increased liver mass, while the difference in kidney index was not statistically significant (P>0.05). Compared with the Model group, there were no statistically significant differences in the liver index and kidney index of rats in the three treatment groups (P>0.05), indicating that the hypoglycemic prescription and metformin had no drug toxicity. Figure 4 .

[0065] 5.5 Effect of the Jiangtang prescription on pancreatic tissue pathology in rats with type 2 diabetes.

[0066] After 4 weeks of drug intervention, the pancreatic islets of rats in the NC group were intact in morphology, with a large number of islet cells, clear boundaries, neat arrangement, and rich cytoplasm. Compared with the NC group, the pancreatic islets of rats in the Model group were irregular in morphology, with obvious cell atrophy, necrosis, and edema, and their pathological scores were significantly increased (P<0.01). Compared with the Model group, the pancreatic islet morphology of rats in the three treatment groups was improved, with an increased number of cells, more regular arrangement, and reduced cell edema, especially in the JTF+MET group. The islet cells had clear boundaries and neat arrangement, and their pathological scores were significantly reduced (P<0.01), indicating that the hypoglycemic prescription can effectively reduce the edema and necrosis of islet cells in rats with type 2 diabetes. Figure 5 , black arrows indicate intact pancreatic islets.

[0067] A type 2 diabetic rat model was established by feeding with a high-sugar and high-fat diet combined with intraperitoneal injection of a small dose of STZ. After four weeks of continuous intervention with the glucose-lowering prescription, the glucose-lowering prescription significantly alleviated the symptoms of "three mores and one less" in type 2 diabetic rats; ELISA results showed that the glucose-lowering prescription effectively reduced the levels of serum GSP and FINS; histopathological staining results showed that the glucose-lowering prescription significantly and effectively reduced the edema and necrosis of pancreatic islet cells in DM rats; this showed that the glucose-lowering prescription can effectively improve insulin resistance, protect pancreatic islet cells, and promote insulin secretion, thereby playing a role in treating type 2 diabetes, and has a tangible therapeutic effect.

[0068] The above description is only a preferred embodiment of the present invention and is not intended to limit the scope of the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A Chinese medicine composition for treating type 2 diabetes, characterized in that: It is composed of the following ingredients: chamomile, corn silk, Jerusalem artichoke, chaga, and white snow tea.

2. The Chinese medicine composition for treating type 2 diabetes according to claim 1, characterized in that: The Chinese medicine composition is composed of the following raw materials by weight: 6g of chamomile, 6g of corn silk, 6g of Jerusalem artichoke, 6g of chaga, and 6g of white snow tea.

3. Use of the Chinese medicine composition according to any one of claims 1 to 2 in the preparation of a medicament for treating type 2 diabetes.

4. A pharmaceutical composition, characterized in that The components include the traditional Chinese medicine composition according to any one of claims 1 to 2 and a pharmaceutically acceptable carrier.

5. The pharmaceutical composition according to claim 4, characterized in that The dosage form of the pharmaceutical composition is a pharmaceutically acceptable dosage form.

6. Use of the pharmaceutical composition according to any one of claims 4 to 5 in the preparation of a medicament for treating type 2 diabetes.

7. A method for preparing the Chinese medicine composition for treating type 2 diabetes according to claim 1, characterized in that: The following steps are involved: Weigh chamomile, corn silk, Jerusalem artichoke, chaga, and white snow tea according to weight, add water and boil, and collect the decoction.

8. The method for preparing the Chinese medicine composition for treating type 2 diabetes according to claim 7, characterized in that: The decoction with water is performed by using 8 times the amount of distilled water, soaking overnight, adding 8 times the amount of water for the first decoction and decocting for 2 hours, and adding 6 times the amount of water for the second decoction and decocting for 1.5 hours, and the medicinal liquids obtained by filtering the two decoctions are mixed to obtain the Chinese medicine composition.

Images